HTG Transcriptome Panel - Early Adopter Program

We thank our early adopters for being our customers, advocates and helping us shape the future of gene expression profiling with the HTG Transcriptome Panel. We are grateful for your support and realize that you are the essential part of what powers innovation and breakthroughs.

The University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center

Saint John’s Cancer Institute

Saint John’s Cancer Institute

Duke University Medical Center

Duke University Medical Center

Fundación Instituto Valenciano de Oncologia

Fundación Instituto Valenciano de Oncologia

Tyrolpath Obrist Brunhuber GmbH

Tyrolpath Obrist Brunhuber GmbH


        University Hospital Essen

University Hospital Essen

Johannes Wesling Hospital Minden

Johannes Wesling Hospital Minden

Alacris Theranostics GmbH

Alacris Theranostics GmbH

Centre Leon Berard

Centre Leon Berard

The Larner College of Medicine at the University of Vermont

The Larner College of Medicine at the University of Vermont

Mayo Clinic

Mayo Clinic

Universitätsklinikum Tübingen

Universitätsklinikum Tübingen

Institute of Immunobiology, Kantonsspital St. Gallen

Institute of Immunobiology, Kantonsspital St. Gallen

University Hospital Basel

University Hospital Basel

Imperial College London

Imperial College London

Featured Publication

Overview of the Design and Performance of the HTG Transcriptome Panel

This White Paper summarizes the data generated using the HTG Transcriptome Panel from Feasibility through Verification, including comparison to RNA-Seq.
 

READ PUBLICATION

HTG Molecular News & Events

HTG Molecular Diagnostics to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

TUCSON, Ariz. , Sept. 08, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will participate in H.C. Wainwright’s 23rd Annual Global Investment Conference ,…

Keep Reading

HTG Molecular Diagnostics Reports Second Quarter 2021 Results

Call scheduled for today, August 12, at 4:30pm ET TUCSON, Ariz. , Aug. 12, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2021…

Keep Reading

HTG’s New HTG Transcriptome Panel Launched with Commercial Availability in the U.S. and Europe

HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the  HTG EdgeSeq technology Intended to serve as one of the technological cornerstones for the  recently announced HTG Therapeutics Business Unit A third white paper highlighting the HTG Transcriptome Panel’s…

Keep Reading

Resources

Find product information, specifications and gene lists here. 

Case Studies

Brochures

Gene Lists

Product Sheets

Tech Notes

Safety Data Sheets

Videos


Support

Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels. 

Log in to your account

Page last updated August 20, 2021

Ready to get started?

HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.

Get in Touch